Dr. Abbey Presented on Retinal Sustained Drug Delivery Research at Retina World Congress
At the recently held Retina World Congress 2026 meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented on the evolving clinical trial landscape for sustained drug delivery in retinal disease. Dr.
read more
Dr. Abbey Presented Study Results of Two Investigational Wet AMD Treatments at Clinical Trials Summit
This past weekend, Texas Retina’s Director of Clinical Research for Dallas Ashkan M. Abbey, MD, led two presentations at the annual Clinical Trials at the Summit (CTS) meeting in Las Vegas, which
read more
Texas Retina Clinical Research Coordinator Rachel McCullough Participates in Panel Discussion for LUGANO and LUCIA Clinical Trials
At a recent meeting in San Antonio, Texas Retina Clinical Research Coordinator Rachel McCullough participated in a panel discussion with study coordinators for EyePoint Pharmaceuticals’ pivotal Phase III LUGANO and LUCIA clinical
read more
Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more